Long after wounds close, the nervous system can remain locked in a state of alarm — not because danger persists, but because the molecular machinery governing sensation has been altered. Researchers at Boston University have identified a protein called RGS4, residing within peripheral sensory nerves, whose activity appears to sustain this abnormal hypersensitivity. By targeting RGS4 rather than masking the sensation of pain, scientists may have found a way to restore the nervous system to its natural equilibrium — a distinction that separates healing from mere suppression.
Boston University researchers identify RGS4 protein as potential chronic pain target
Interrupt the biological process that causes pain to persist
Mark
So the basic problem is that injured nerves keep sending pain signals even after they should have healed. What's different about this discovery?
Mimi
The researchers found that the nerve cells themselves change at a molecular level. It's not just that the signal is being sent—the nerve becomes fundamentally more sensitive. RGS4 is the protein that seems to control that sensitivity.
Luke
But this is in experimental models, right? We should be clear about that.
Mimi
Yes, they tested it in several animal models across different pain conditions. The important part is they also confirmed the same protein exists in human nerve tissue.
Mark
So if you block RGS4, what happens?
Mimi
In the models, the nervous system calmed down. The abnormal pain sensitivity reversed. They also did the opposite—increased RGS4—and the healthy models became more sensitive to pain.
Luke
That's a clean result in a controlled setting. But moving from blocking a protein in an animal model to developing a drug that works safely in humans is a very different challenge.
Mimi
True. But the location matters. RGS4 is in the sensory nerves outside the brain and spinal cord, so theoretically you could target it locally rather than affecting the whole nervous system.
Mark
That would mean fewer side effects than morphine?
Mimi
Potentially. Morphine just masks the pain. This approach would theoretically interrupt the process that causes pain to become chronic in the first place.
Luke
The researchers say that's the goal. But we don't have a drug yet, and we don't know if blocking RGS4 in humans would actually work or what the side effects might be.
Mark
What's the timeline for getting something to patients?
Mimi
That's not clear from this research. This is foundational work identifying the target. Drug development would come next.
El Pulso
- Chronic pain is not simply unresolved injury — it is a nervous system that has been molecularly rewired to keep screaming long after the original wound has closed.
- Current opioid treatments offer relief without resolution, leaving millions dependent on drugs that dull sensation while the underlying biological disruption continues unchecked.
- Boston University researchers found that blocking the RGS4 protein in sensory nerve cells reversed pain hypersensitivity in experimental models across nerve injury, surgical, inflammatory, and chemotherapy-related pain conditions.
- Because RGS4 sits in peripheral nerves rather than the brain, future therapies could act with surgical precision — targeting the source of the problem without flooding the entire nervous system.
- The same molecular pathway was confirmed in human nerve tissue, moving this discovery from a laboratory curiosity toward a plausible clinical horizon.
Long after wounds close, the nervous system can remain locked in a state of alarm — not because danger persists, but because the molecular machinery governing sensation has been altered. Researchers at Boston University have identified a protein called RGS4, residing within peripheral sensory nerves, whose activity appears to sustain this abnormal hypersensitivity. By targeting RGS4 rather than masking the sensation of pain, scientists may have found a way to restore the nervous system to its natural equilibrium — a distinction that separates healing from mere suppression.
Pain that outlasts its cause is one of medicine's most persistent failures. A damaged peripheral nerve, rather than quieting after injury, can continue firing distress signals indefinitely — gradually rewiring the spinal cord and brain until the entire sensory system becomes hyperactive. For decades, the answer has been opioids: drugs that lower the volume without ever addressing why the dial got stuck.
Researchers at Boston University's Chobanian & Avedisian School of Medicine have now identified a more precise target. A protein called RGS4, embedded within sensory nerve cells, appears to function as a molecular switch governing pain sensitivity. When the team blocked RGS4 in experimental models, the nervous system's abnormal reactivity reversed and returned to baseline. When they artificially elevated RGS4 in healthy models, those subjects became more pain-sensitive. The protein, it turns out, can be dialed up or down — and chronic pain may depend heavily on which direction it goes.
The mechanism held across multiple pain types: nerve injury, postoperative pain, inflammation, and chemotherapy-induced damage. More importantly, the same pathway was identified in human nerve tissue, suggesting the laboratory findings carry real translational weight.
What distinguishes this approach is geography as much as biology. Because RGS4 resides in peripheral nerves — outside the brain and spinal cord — treatments targeting it could act locally, sparing patients the systemic side effects that make current pain management so difficult. Rather than suppressing the sensation of pain after it has taken hold, a therapy aimed at RGS4 could theoretically interrupt the transition from acute injury to chronic condition altogether. The findings, published in Science Signaling, mark not an endpoint but an opening — toward treatments that restore the nervous system rather than simply quiet it.
Pain that lingers long after an injury heals represents one of medicine's most stubborn puzzles. A peripheral nerve—one of the countless fibers running through the body outside the brain and spinal cord—can sustain damage that never quite resolves. Instead of settling, the injured nerve keeps firing pain signals, relentlessly, month after month. Over time, this constant barrage rewires the spinal cord and brain itself. The nervous system's sensory and emotional circuits become hyperactive, amplifying the pain signal until the volume dial seems stuck at maximum.
For decades, the standard response has been to reach for morphine or other opioids—drugs that dull the pain without addressing what caused it in the first place. They work for some patients, but not all, and the side effects can be severe. Researchers at Boston University's Chobanian & Avedisian School of Medicine have now identified what may be the actual culprit: a protein called RGS4 that sits in the sensory nerve cells themselves. When they blocked this protein in experimental models, something remarkable happened. The nervous system quieted down. The abnormal pain sensitivity reversed. The system returned to baseline.
Venetia Zachariou, who led the work as chair of the pharmacology, physiology, and biophysics department, explained the significance: the sensory nerves themselves undergo molecular changes that keep them unusually reactive. By reducing RGS4 activity, the experimental models recovered from that abnormal state. Conversely, when the researchers increased RGS4 levels in otherwise healthy models, those animals became more sensitive to pain. The protein, in other words, acts as a switch—one that can be turned down to restore normal function or turned up to induce hypersensitivity.
The team tested this mechanism across multiple pain conditions: peripheral nerve injury, postoperative pain, inflammatory pain, and chemotherapy-induced nerve damage. In each case, manipulating RGS4 produced measurable changes in how the nervous system responded. Critically, the researchers found that the same molecular machinery exists in human nerve tissue, suggesting the findings might translate beyond the laboratory.
What makes this discovery potentially transformative is not just that it identifies a target, but that the target sits in the peripheral nerves themselves—outside the brain and spinal cord. This location matters enormously. It means future treatments could be designed to act locally, on the sensory nerves where the problem originates, rather than flooding the entire nervous system with drugs. Such precision could mean fewer side effects and more effective intervention.
The current paradigm treats chronic pain as a symptom to mask. Zachariou and her team are proposing something different: interrupt the biological process that causes pain to persist in the first place. Rather than waiting for chronic pain to develop and then trying to suppress it, a therapy targeting RGS4 could theoretically prevent the transition from acute injury to chronic condition. The research appears in Science Signaling, and the pathway is now open for the next phase—translating these findings into drugs that might one day reach patients whose pain has outlasted any reasonable healing timeline.
Citas Notables
Rather than simply masking pain after it becomes chronic, we hope this work contributes to therapies that interrupt the biological processes that cause pain to persist in the first place.— Venetia Zachariou, Boston University Chobanian & Avedisian School of Medicine
Quieres la nota completa?
Lee el original en News-Medical ↗
Education